Karyopharm Therapeutics Inc. (KPTI)
| Market Cap | 147.29M |
| Revenue (ttm) | 146.03M |
| Net Income (ttm) | -143.10M |
| Shares Out | 115.07M |
| EPS (ttm) | -1.25 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,305,054 |
| Open | 1.420 |
| Previous Close | 1.380 |
| Day's Range | 1.220 - 1.420 |
| 52-Week Range | 0.617 - 4.110 |
| Beta | 0.06 |
| Analysts | Buy |
| Price Target | 5.67 (+342.97%) |
| Earnings Date | May 2, 2024 |
About KPTI
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myelom... [Read more]
Financial Performance
In 2023, KPTI's revenue was $146.03 million, a decrease of -7.03% compared to the previous year's $157.07 million. Losses were -$143.10 million, -13.43% less than in 2022.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for KPTI stock is "Buy." The 12-month stock price forecast is $5.67, which is an increase of 342.97% from the latest price.
News
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass. , April 1, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company...
Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences
NEWTON, Mass. , March 6, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company...
Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
– Total Revenue of $146 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $112 Million for Full Year 2023, Meeting Company's Guidance – – Top-Line Data Readouts from Three Pivotal Phase 3 T...
Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
-- Conference Call Scheduled for Thursday, February 29, 2024, at 8:00 a.m. ET -- NEWTON, Mass.
Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives
– Accelerating Innovation and Growth Strategy with Top-Line Data Readouts Expected in 2H 2024 and 2025 from Three Pivotal Phase 3 Studies Evaluating Selinexor in Multiple Myeloma, Endometrial Cancer a...
Karyopharm to Present at 42nd Annual J.P. Morgan Healthcare Conference
NEWTON, Mass. , Jan. 3, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company'...
Antengene Announces Inclusion of XPOVIO® (selinexor) in 2023 China's National Reimbursement Drug List
SHANGHAI and HONG KONG , Dec. 13, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to d...
Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Myelofibrosis Patients, with no SVR or TSS Progressions Observed As of the Data Cutoff(1)
Biomarker Data from Phase 1 Study of Selinexor in Combination with Ruxolitinib in Treatment-Naïve Myelofibrosis (MF) Suggestive of Disease Modification Data Reinforce the Potential for Selinexor in Co...
Antengene Announces XPOVIO® Regulatory Approval in Macau for the Treatment of Relapsed and/or Refractory Multiple Myeloma
XPOVIO® (selinexor) is the first and only exportin 1 (XPO1) inhibitor approved in Macau. XPOVIO® has received regulatory approvals in 42 countries and regions including Mainland of China, Taiwan Ch...
Karyopharm to Participate at Upcoming Investor Conferences
NEWTON, Mass. , Nov. 8, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company'...
Karyopharm Announces New Preliminary Data in Overall Survival (OS) in Selinexor-Treated Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer as Part of Pre-Specified Exploratory Subgroup Analysis of the SIENDO Study
Long-Term Safety and Efficacy Data from SIENDO Study in the TP53 Wild-Type Exploratory Subgroup Showed Signals of Improvement in Overall Survival (OS) Regardless of Mismatched Repair Status (MMR) Med...
Karyopharm Announces Presentations at the 65th American Society of Hematology Annual Meeting and Exposition (ASH)
Long-Term Selinexor Data in Myelofibrosis will be Presented as Part of Oral Presentation NEWTON, Mass. , Nov. 2, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage ph...
Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
– Achieved Third Quarter 2023 Total Revenue of $36.0 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $30.2 Million – – Maintains Full Year 2023 Total Revenue Guidance of $145 Million to $...
Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma
— Phase 1b/2 Trial Will Investigate Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma Progressing after T-cell Immunotherapies – — Expected to be Initi...
Karyopharm to Report Third Quarter 2023 Financial Results on November 2, 2023
-- Conference Call Scheduled for Thursday, November 2, 2023, at 8:00 a.m. ET -- NEWTON, Mass.
Karyopharm to Present Selinexor Data at the 2023 International Myeloma Society Annual Meeting and European Society of Gynaecological Oncology 2023 Annual Meetings
NEWTON, Mass. , Sept. 26, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that several ab...
Karyopharm Appoints Zhen Su, MD, MBA to its Board of Directors
NEWTON, Mass. , Sept. 1, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment ...
Antengene Enters into Commercialization Partnership with Hansoh Pharma for First/Only-in-Class XPO1 Inhibitor XPOVIO®(selinexor) in the Mainland of China
- Antengene and Hansoh Pharma to enter into collaboration agreement involving commercialization of XPOVIO® in the mainland of China, broadening coverage and improving access of the drug to patien...
Karyopharm Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
– Achieved Second Quarter 2023 Total Revenue of $37.6 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $28.5 Million – – Maintains Full Year 2023 Total Revenue Guidance of $145 Million to ...
Karyopharm to Report Second Quarter 2023 Financial Results on August 2, 2023
-- Conference Call Scheduled for Wednesday, August 2, 2023, at 8:00 a.m. ET -- NEWTON, Mass.
Karyopharm Announces Presentation of Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer
Signal of PFS Improvement in SIENDO for Selinexor-Treated Patients was Observed Only in Subgroup Who are TP53 Wild-Type with a Median Progression-Free Survival of 27.4 Months Median PFS Not Reached f...
Karyopharm Announces Updated Exploratory Subgroup Analysis from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer to be Presented at ASCO Plenary Series on July 25th
- Data Provide Further Support for Company's Ongoing Phase 3 Study Evaluating Selinexor as Maintenance Therapy Following Systemic Therapy in Patients with Advanced or Recurrent TP53 Wild-Type Endomet...
Karyopharm Receives FDA Fast Track Designation for Selinexor for the Treatment of Myelofibrosis
– Regulatory Designation Includes Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis and Post-Polycythemia Vera Myelofibrosis – – Pivotal Phase 3 Study of Selinexor and Ruxolitinib in...
Antengene Announces XPOVIO® Regulatory Approval in Hong Kong for the Treatment of Relapsed and/or Refractory Multiple Myeloma
XPOVIO® (selinexor) is the first and only XPO1 inhibitor approved in Hong Kong XPOVIO® has received regulatory approvals in 41 countries and regions including the United States, Israel, the United...
Karyopharm Initiates Pivotal Phase 3 Study of XPO1 Inhibitor Selinexor and Ruxolitinib in JAK Inhibitor (JAKi) Naïve Myelofibrosis
Phase 3 Study is Supported by Previously Presented Phase 1 Study Results, Including a 78.6% SVR35 and 58.3% TSS50 in Intent to Treat Patients at Week 24 at the 60mg Dose NEWTON, Mass. , June 28, 2023 ...